Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.36 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.36 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 5/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3039471 | 1.00 | TXNRD1 (0.36) | TXNRD1TXNRD3TXNRD2ALDH1A1HPGD | |
| SCHEMBL13481942 | 0.89 | TXNRD1 (0.37) | TXNRD1TXNRD3TXNRD2ALDH1A1HPGD | |
| SCHEMBL8116646 | 0.87 | TXNRD1 (0.40) | TXNRD1TXNRD3TXNRD2ALDH1A1NPC1 | |
| SCHEMBL10305220 | 0.84 | TXNRD1 (0.39) | TXNRD1TXNRD3TXNRD2ALDH1A1NPC1 | |
| SCHEMBL8125480 | 0.84 | TXNRD1 (0.39) | TXNRD1TXNRD3TXNRD2ALDH1A1NPC1 | |
| SCHEMBL3027768 | 0.83 | MAPT (0.39) | TXNRD1TXNRD3TXNRD2ALDH1A1HPGD | |
| SCHEMBL4361272 | 0.81 | TXNRD1 (0.36) | TXNRD1TXNRD3TXNRD2ALDH1A1NPC1 | |
| SCHEMBL13222372 | 0.81 | MAPT (0.44) | TXNRD1TXNRD3TXNRD2ALDH1A1NPC1 | |
| SCHEMBL3021540 | 0.80 | DRD2 (0.47) | ALDH1A1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL3032880 | 0.80 | DRD2 (0.47) | ALDH1A1NPC1RAB9AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8466296-B2 | Compounds and processes for preparing substituted aminomethyl-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-ones | LIGAND PHARMACEUTICALS (US) | 2013-06-18 | — | — | US | disclosed |
| EP-2046771-B1 | SYNTHESIS OF A COMPOUND WHICH IS SUITABLE AS INTERMEDIATE IN THE SYNTHESIS OF OXINDOLEDIOXANE DERIVATIVES | WYETH LLC (US) | 2012-07-11 | — | — | EP | disclosed |
| EP-2046771-B1 | SYNTHESIS OF A COMPOUND WHICH IS SUITABLE AS INTERMEDIATE IN THE SYNTHESIS OF OXINDOLEDIOXANE DERIVATIVES | WYETH LLC (US) | 2012-07-11 | — | — | EP | disclosed |
| US-20100217012-A1 | COMPOUNDS AND PROCESSES FOR PREPARING SUBSTITUTED AMINOMETHYL-2,3,8,9-TETRAHYDRO-7H-1,4-DIOXINO[2,3-e]INDOL-8-ONES | NEUROGEN CORPORATION (US) | 2010-08-26 | — | — | US | disclosed |
| US-7662979-B2 | cyanation; dopamine autoreceptor agonists and partial agonists at postsynaptic dopamine D2 receptor; for treating dopaminergic disorders such as schizophrenia, schizoaffective disorder, Parkinson's disease, Tourette's syndrome, hyperprolactinemia, and drug addiction | WYETH (US) | 2010-02-16 | — | — | US | disclosed |
| US-7662979-B2 | cyanation; dopamine autoreceptor agonists and partial agonists at postsynaptic dopamine D2 receptor; for treating dopaminergic disorders such as schizophrenia, schizoaffective disorder, Parkinson's disease, Tourette's syndrome, hyperprolactinemia, and drug addiction | WYETH (US) | 2010-02-16 | — | — | US | disclosed |
| US-7662979-B2 | cyanation; dopamine autoreceptor agonists and partial agonists at postsynaptic dopamine D2 receptor; for treating dopaminergic disorders such as schizophrenia, schizoaffective disorder, Parkinson's disease, Tourette's syndrome, hyperprolactinemia, and drug addiction | WYETH (US) | 2010-02-16 | — | — | US | disclosed |
| CN-101448814-A | Synthesis of a compound which is a suitable intermediate in the synthesis of oxindoledioxane derivatives | WYETH CORP (US) | 2009-06-03 | — | — | CN | disclosed |
| EP-2046771-A2 | SYNTHESIS OF A COMPOUND WHICH IS SUITABLE INTERMEDIATE IN THE SYNTHESIS OF OXINDOLEDIOXANE DERIVATIVES | Wyeth (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20070293686-A1 | Oxindoledioxans, synthesis thereof, and intermediates thereto | WYETH (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293686-A1 | Oxindoledioxans, synthesis thereof, and intermediates thereto | WYETH (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293686-A1 | Oxindoledioxans, synthesis thereof, and intermediates thereto | WYETH (US) | 2007-12-20 | — | — | US | disclosed |
| WO-2007139998-A2 | SYNTHESIS OF A COMPOUND WHICH IS A SUITABLE INTERMEDIATE IN THE SYNTHESIS OF OXINDOLEDIOXANE DERIVATIVES | WYETH (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007139998-A2 | SYNTHESIS OF A COMPOUND WHICH IS A SUITABLE INTERMEDIATE IN THE SYNTHESIS OF OXINDOLEDIOXANE DERIVATIVES | WYETH (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293686-A1 | Oxindoledioxans, synthesis thereof, and intermediates thereto | HTR5A, OPRL1, SLC6A3 | TXNRD1 97/4885TXNRD3 68/4885TXNRD2 87/4885 |
| US-20100217012-A1 | COMPOUNDS AND PROCESSES FOR PREPARING SUBSTITUTED AMINOMETHYL-2,3,8,9-TETRAHYDRO-7H-1,4-DIOXINO[2,3-e]INDOL-8-ONES | MTNR1A, HTR3C, MTNR1B | TXNRD1 1143/4885TXNRD3 468/4885TXNRD2 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.